BSE Announcements  
 
Can Fin Homes
CARE Ratings (CareEdge Ratings) has reaffirmed ratings of long-term bank facilities and debt instruments of Can Fin Homes (CFHL) at CARE AAA+; Stable. Reaffirmation continues to factor CFHL's strong parentage, with Canara Bank (rated CARE AAA; Stable) as the primary shareholder holding 29.99% as on 30 September 2025. The parent provides board level oversight, strategic guidance and shared brand franchise. Despite its modest shareholding, Canara Bank considers CFHL a strategically important entity and has reiterated its commitment to provide support while maintaining its equity stake.

Supported by its parentage and track record, CFHL enjoys strong financial flexibility, enabling it to raise funds from diversified sources at competitive rates. Ratings also reflect CFHL's relatively low-risk loan portfolio, with a dominant share of salaried borrowers, its continued healthy financial performance, stable profitability, strong asset quality, and adequate capitalisation levels. These strengths outweigh credit challenges arising from high leverage, regional concentration and competitive housing finance segment.
Fynx Capital
Fynx Capital announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 11 December 2025.
Transchem
Transchem will hold a meeting of the Board of Directors of the Company on 21 November 2025.
Marksans Pharma

Marksans Pharma announced USFDA final approval of the Company's wholly owned subsidiary Marksans Pharma Inc.'s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC). This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC (Kenvue) NDA - 019860.

 Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.
Prev  || Next